🇺🇸 FDA
Pipeline program

ADX10059

ADX10059-205

Phase 2 small_molecule completed

Quick answer

ADX10059 for Gastroesophageal Reflux is a Phase 2 program (small_molecule) at Addex Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Addex Therapeutics
Indication
Gastroesophageal Reflux
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials